PBH

AI Memo

Prestige Consumer Healthcare

As of 2026-08-08/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

—

Key catalyst

FY27 outlook raised • 2026-08-06

Expected move: +15%

Biggest risk

Net debt was approximately $2B, reported EPS fell to $0.61 from $0.95, and acquisition/Pillar5 remediation costs pressured GAAP profitability. Clear Eyes supply volatility and a challenging consumer backdrop remain material execution risks.

Invalidation

Break below $46 or thesis failure.

What would change my mind?

The Q1 print showed positive organic growth across Gastrointestinal and Dermatological categories, improved adjusted EPS, strong cash flow, and a raised outlook. Acquisitions could add durable growth and future synergies.

Research note

Recommendation

—

Confidence

high

As of

2026-08-08

Base target

$63

p=50%

Bull target

$72

p=25%

Bear target

$46

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 FY27 operating beat
Acquisition integration and deleveraging
Cash-flow-supported maturity extension

BearKey bullets

Acquisition integration, Pillar5 remediation, and related costs may delay margin and cash-flow accretion.
Approximately $2B of net debt increases sensitivity to interest costs and acquisition execution.
Management cited continued volatility in Clear Eyes supply and a challenging consumer environment.

WatchKey bullets

FY27 outlook raised

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Base case: $63 (p=50%)

Bull/Bear spread: +31% / -16%

Vs latest close: Bull +31% · Base +15% · Bear -16%

Scenario probabilities

Bull Target: $72 (p=25%)Base Target: $63 (p=50%)Bear Target: $46 (p=25%)

Commentary

Post-earnings evidence is directionally positive: the company reported an operating beat and raised FY27 guidance. The August 7 anchor was $54.85, but a precise post-release percentage reaction and verified analyst revision set are unavailable. Social coverage is absent, so confidence remains below that of a fully covered earnings thesis.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 FY27 operating beat
Acquisition integration and deleveraging
Cash-flow-supported maturity extension

Scenarios

Bull Target (Scenario probability)

$72 / p=25% prob

Base Target (Scenario probability)

$63 / p=50% prob

Bear Target (Scenario probability)

$46 / p=25% prob

Price $55 as of 2026-08-07

Nearest Scenario: Base (∆ 15%)

Targets vs latest close: Bull +31% · Base +15% · Bear -16%

Sentiment & Exposure

News Sentiment (30d)

0.68

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-06
FY27 outlook raised
The company raised FY27 revenue guidance to $1.290B-$1.315B, adjusted EPS to $4.55-$4.65, and adjusted free cash flow to at least $270M, primarily reflecting the Breathe Right and LaCorium acquisitions. [#SEC-8K-2026-08-06]
Prob 85.00% • Move 6.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

Q1 FY27 operating beat
2026-08-06
Q1 revenue rose 6.5% to $265.7M, organic growth was 3.2%, adjusted EPS increased to $0.98 from $0.95, and adjusted free cash flow reached $83.7M. Management said performance exceeded sales and earnings expectations. [#SEC-8K-2026-08-06]
Prob 90% • Move 4% • Priced-in 65%

Long-term Catalysts

Months to a year

Acquisition integration and deleveraging
2027-03-31
Breathe Right contributed approximately $6M of Q1 revenue, while LaCorium is described as a roughly $40M annual-revenue business with approximately $12M of EBITDA including expected synergies. Management expects increasing accretion as integration progresses. [#SEC-8K-2026-08-06] [#PR-EARNINGS-2026-07-06]
Prob 65% • Move 10% • Priced-in 45%
Cash-flow-supported maturity extension
2027-03-31
Q1 adjusted free cash flow was $83.7M, and $400M of new 6.25% notes due 2034 replaced notes due in 2028, moving the closest debt maturity to 2031. [#SEC-8K-2026-08-06]
Prob 60% • Move 7% • Priced-in 50%

Risks

Acquisition integration, Pillar5 remediation, and related costs may delay margin and cash-flow accretion.
Approximately $2B of net debt increases sensitivity to interest costs and acquisition execution.
Management cited continued volatility in Clear Eyes supply and a challenging consumer environment.
Reported Q1 gross profit and operating income declined year over year despite revenue growth.
Tariffs, inflation, labor shortages, foreign exchange, competitive pressure, and supplier or logistics disruption could affect results.

Peers

Symbol	Summary
AMGN	Broad large-cap biopharma comparator only; not a direct OTC consumer-health peer, so valuation comparison is weak.
GILD	Broad sector comparator only; business mix and growth drivers differ materially from PBH.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

AI Stock Memo: PBH - Prestige Consumer Healthcare - RankAlpha